Summary: In the development of cytotoxic T lymphocyte (CTL)-mediated immunotherapy, the identification of CTL epitopes is of crucial importance. Binding of a peptide to major histocompatibility complex (MHC) class I molecules is one of the prerequisites for its function as a CTL epitope. We describe the technique, validation, and application of a simple cellular assay, intended for the screening of peptides for binding, that can be applied to any human leukocyte antigen (HLA) allele. Reconstitution of peptides in MHC class I molecules after elution by acid treatment was previously shown to be possible in specially engineered cell lines expressing only one type of MHC class 1, and was applied for the HLA-A*0201 aliele. We now report the optimal conditions for application of this type of binding assay to the HLA-A*030I allele. The adaptations that were necessary to make the technique operational for HLA-A*030l are shown in detail. These consisted of lowering the pH during acid treatment to 2.9 and lengthening the duration of elution to 90 s. Furthermore, immediate aspiration of eluted peptides appeared to be essential for this allele. We found also that the use of Epstein-Barr virus (EBV)-transformed B cell lines (B-LCL) yields results similar to those of the use of cell lines expressing only one specific MHC class 1 allele. Homozygosity for the desired HLA allele improves the sensitivity of the assay, but heterozygous cells can also be employed. Finally, we applied this technique to a search for HLA-A*030I binding peptides derived from carcinoembryonic antigen (CEA). Of a set of 34 CEAspecific peptides that fit with a specified HLA-A*0301-binding motif, we identified a set of six peptides with high binding affinity to this allele. These peptides can be regarded as potential CTL epitopes. Key Words: HLA-A*030l-CEA-Peptide binding-Elution-Binding affinity.
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The T2-binding assay, a simple cellular assay that measures upregulation of MHC class I on a peptide processing-defective cell line after overnight incubation with exogenous peptide, has been used successfully to detect peptides binding to human leukocyte antigen (HLA)-A*0201 (8, 12, 13) . However, its use is limited to this allele, as it depends on the use of the processing-defective 174 CEM.T2 cell line. Although the HLA-A*0201 allele is one of the most frequently expressed class I alleles among the different ethnic populations (14) , only inclusion of various other alleles will allow the development of CTL-mediated immunotherapy for the significant fraction of the population that does not express HLA-A*0201. Other assays are required that may be adopted for various HLA alleles to test peptide binding.
Recently a cellular binding assay was described (9) in which peptides presented in the MHC class I of C1R cell lines (immortalized B-cell lines modified to express only one HLA allele) were eluted according to a method first described by Sugawara et al. (15) . Reconstitution of HLA-A*0201 was studied by staining with a monoclonal antibody against MHC class I, W6/32. This assay is simple to perform, and the principle can be applied to any HLA allele. However, its application is limited to those alleles of which a C1R transfectant is available. , A molecular binding assay has been described (11) in which peptides that are tested for binding to the purified class I molecules compete for this binding with specific radiolabeled standard peptides. As with other molecular binding assays (7) , the principle can be employed for any class I molecule, but the assays involve the use of radioactive iodine and purified MHC class I molecules.
We developed a technique to use B-LCL lines for a cellular binding assay based on the same principle as previously described in the so-called peptidereconstitution assay (9) , because B-LCL lines expressing any desired HLA phenotype can be obtained rather easily by Epstein-Barr virus (EBV) transformation of peripheral blood lymphocytes of a blood donor expressing the desired phenotype. Under acid conditions, peptide is eluted from the MHC class I molecules, resulting in denaturation of the trimolecular complex consisting of HLA, peptide, and p-2 microglobulin (p2M). In the presence of p2M, exogenous peptide with adequate binding affinity will bind to empty MHC class 1 at the cell surface, thus reconstituting the trimolecular complex, and only such a configuration is recognized by monoclonal antibodies like BB 7.2 (for HLA-A2) and GAP A3 (for HLA-A3).
We compared the use of B-LCL lines, both homozygous and heterozygous for HLA-A*0201 and HLA-A*0301. For HLA-A*0301 we also compared these B-LCLs with the C1R A3 cell line.
Once optimal conditions had been established for the peptide-reconstitution assay in HLA-A*0201 and HLA-A*0301, results from our assay were compared with those obtained with identical peptides in other assays.
Carcinoembryonic antigen (CEA) is a physiologic glycoprotein that is grossly overexpressed in most colorectal cancers and many other carcinomas (16) (17) (18) because of a failure of excretion in malignant cells (19, 20) . This overexpression appears to be limited to carcinoma in adult humans (21) . Because CEA might therefore be a very attractive target for CTL-mediated immunotherapy, we applied the technique for identification of CEA-derived peptides with high-affinity binding to HLA-A*0301.
MATERIALS AND METHODS

Cell Lines
The B-LCL lines used in the experiments were JY, an HLA-A*0201 homozygous cell line; EKR, an HLA-A*0301 homozygous cell line; and D-O, a heterozygous cell line expressing both HLA-A*0201 and HLA-A*0301. We used the C1R A3 cell line, an HLA-A and HLA-B knockout B-cell line transfected with HLA-A*0301. Furthermore, we used the human processing-defective cell line 174 CEM.T2 (T2) (22) . (Both the C1R A3 and T2 cell lines were kindly provided by P. Creswell, Department of Immunology, Yale University, New Haven, CT, U.S.A.)
Cells were cultured at 37°C, 5% CO 2 , and RPMI 1640 Dutch modification (Gibco, Life Technologies, Paisley, Scotland), supplemented with 2 mM glutamine (referred to as RPMI medium), 10% fetal calf serum (PCS) and 5 x 10~5 M 2-mercaptoethanol (for the B-LCL lines) or Iscove's modification of Dulbecco's medium (IMDM; Gibco) supplemented with 10% ECS and 2 mM glutamine (for the C1R A3 and T2 cell lines). Cells were always supplied with fresh culture medium the day before an experiment, and adjusted to between 0.5 x !0 6 and l x 10 6 cells/ml.
Antibodies
The sources of the anti-HLA-A2 and -HLA-A3 antibodies were hybridoma culture supernatant of BB 7.2 (HB82-ATCC) and GAP A3 (HB 122-ATCC) [American Tissue Type Collection (ATCC), Rockvine, MD, U.S.A.], respectively (23, 24) . To confirm allele specificity, al! cell lines used in the experiments were stained with both antibodies and a second-antibody-only negative control (GaM FITC).
Peptides
For control purposes, we used peptides with known HLA-A*0201 and HLA-A*0301 binding parameters, as shown in Table 1 .
Our group previously described binding motifguided computerized selection of peptides potentially binding to HLA-A*0201 (8, 25) . We used this computer scoring system and thus selected all CEA-specific peptides, eight to 11 amino acids long, that fit with the following binding motif for HLA-A*0301, based on the observations of Kubo et al. (26) , and a comprehensive list of peptides naturally occurring in HLA-A*0301 (27, 28) : all peptides had L/l/V/M (one-letter amino acid code) at position 2 from the N-terminus, and K/R/Y at the C-terminus. These 34 peptides were synthesized and dissolved as described (8) , adjusted to a pH between 6.5 and 7.5, aliquoted, and stored at -20°C.
Peptide-Reconstitution Assay
The peptide-reconstitution assay is a three-step procedure, consisting of elution (step 1), reconstitution of the trirnolecular complex associated with a specific monoclonal antibody (step* 2), and counterstaining with a fluorescent second antibody and fixation for flowcytometric analysis (step 3).
Step 1. 7 million cells were washed twice in 5(f rnl of phosphate-buffered saline (PBS). Supernatant was aspirated, the pellet resuspended in the residual PBS, and rested on ice for 10 min. Cells an ice were eluted by carefully rinsing with 3 ml of citrate phosphate buffer [0.131 M citric acid and 0.066 M Na,HPO 4 (adjusted to the desired pH) for 90 s (unless stated otherwise)]. Then 47 ml of IMDM (0°C) without supplements was added, and cells were spun down immediately at 2,000 r/min (690 g) for 3 min, washed again in IMDM, and resuspended in 1.5 ml of RPMI medium.
Step 2. Wells of a 96-well U-bottom cell-culture plate (Costar, Cambridge, MA, U.S.A.) were filled with a saturating amount of 110 ^1 of first antibody, supplemented with fJ2M (final concentration of 1 M,g/ml). Subsequently 25 nl of peptide solution diluted in RPMI medium (maximum final concentration, 400 |Ag/ml) and, finally, 15 pil of the cell suspension was added to each well (final volume, 150 |J).
Step 3. After 4-h incubation at room temperature, the cells were spun down at 1,300 r/min for 5 min, uman immunodefi-washed twice in 100 \t\ of PBS/BSA 1%, and incubated with 50 u,l of FITC-conjugated goat antimouse immunoglobulin (OaM FITC, Boehringer Mannheim, Germany), dissolved 1:100 in PBS/BSA 1% per well at 4°C for 30 min. Cells were washed again, and finally cells were resuspended in 100 n.1 of 0.5% paraformaldehyde in PBS. Cells were analyzed using a Becton-Dickinson FACScan flowcytometer, and the mean fluorescence (mF) was determined.
The following values were calculated: fluorescence index (FI) was defined as the increase of mean fluorescence in the sample (eluted cells incubated with the peptide) over the background as a fraction of that background (background = eluted cells incubated with 25 jj.1 of RPMI instead of peptide):
An FTX0.5 was considered to indicate no significant binding affinity of the peptide for the allele concerned.
It is known from our experience with the T2 assay that serial dilution of the peptide results in an S-shaped curve when FI is plotted against peptide concentration on a logarithmic peptide concentration x axis. The level of the plateau (maximum F!) is correlated with the binding affinity of the peptide in the T2 assay (8,i2) ,
The concentration at which half of the maximum FI is reached (the '/imax value) is inversely correlated with binding affinity in the T2 assay (13) . The '/2max was determined by plotting the Fl against the concentration of peptide. A Vimax in the same range as the values established for known CTL epitopes was considered indicative of high binding affinity.
RESULTS
Effect of pH and Length of Blution
Mild acid treatment of B-LCL for 60 s at pH 3.3 wa£ reported sufficient for elution of HLA-A*0201 mokcules (9) . The same treatment applied even for 90 s resulted in a very moderate decrease of 35% (mF from 320 to 210) of cell surface HLA-A*0301 (Fig. 1) , indicating a relatively low MHC class I dissociating effect of the treatment in both B-LCL and C1R A3.
At a fixed elution time of 90 s, decreasing the pH resulted in a progressive dissociation of the MHC class I complex. HLA-A*0201 complex dissociation occurred at a pH <5, reaching a plateau at pH 3.5. Dissociation of HLA-A*0301 required a pH <3.5, and at pH 2.9, only a hint of a plateau was seen (Fig,  1) . However, down to a pH of 2.9, -85% of cells survived acid treatment, whereas further lowering of the pH resulted in a sudden and sharp decrease in cell survival to 68% at pH 2.75, as determined by trypan blue exclusion (data not shown).
Increasing the duration of acid treatment at a given pH also resulted in progressive dissociation. However, maximum effect was reached after 30 s in HLA-A*0201, whereas 90 s was required for HLA-A*0301 (Fig. 2) .
Under conditions of optimal elution for each allele, an mF level was reached of ~10% of the ïeve! found with cells that had not been eluted (pH 7.4 in Fig. 1) . Dissociation of the HLA-A*0301 complex required more vigorous acid treatment, both in pH and duration, possibly indicating stronger binding forces within the trimolecular complex of HLA-A*0301.
The allele specificity of the antibodies used in these experiments was confirmed by staining all cell lines used with both antibodies and a secondantibody-only negative control (GaM FITC), as shown in Fig. 3 . As a negative control peptide, we used CEA 353-361 (DVGPYECG1, a peptide that never showed any sign of binding to HLA-A*0201 or HLA-A*0301, either in T2 or in our peptide-reconstitution assays).
For all peptides, the FI curves were of identical shape, irrespective of the cell line used (homozygous, heterozygous, or C1R variant for the desired HLA alleie) (Figs. 4 and 5) . However, Vimax values for HIV pol 468-476 and CEA 308-318 were 2 and 20 M-g/ml, respectively, when we used the homozygous ceil line, and 5 and 55 u,g/ml when the heterozygous cell line was employed. For HIV nef 73-82 and HIV pol 468-476, the respective values were 3 and 25 u,g/ml and 5 and 40 jig/ml, and by using the CIR A3 cell line, the respective Vimax values were 2 and 20 (jLg/ml (Figs. 4 and 5) .
', This indicates that the assay may be carried out with cells with either homozygous or heterozygous expression of the HLA alleie tested, but^sensitivity for binding at low peptide concentrations is higher in homozygous cell lines.
Validation of the Assay
The use of peptides with known binding affinity to HLA-A*0201 and HLA-A*0301 enabled us to validate our assay in its ability to quantify binding affinity of peptides. For HLA-A*0201, we tested p53 and CEA peptides, using the HLA-A*0201 homozygous JY cell line, and determined their maximum F! and Vzmax values, to compare these with the results from the T2 assay (!2,13; our observa- tions). ViMax values in both tests did not differ significantly (Table 2) .
For HLA-A*0301, we tested seven peptides derived from HPV 16 E6 and E7, of which the binding affinities to HLA-A*0301 were previously published-^ 1; Table 2 ranked to the published 1C 50 values, the peptide concentration resulting in 50% binding inhibition of the reference peptide). The peptides with the lowest IC 50 (HPV 16 E6 125-133 and HPV 16 E 6 7-15) had '/imax values at the low end of the range we found (5 and 6 u.g/ml, respectively). The peptides with the highest IC 50 (HPV 16 E 6 143-151 and HPV 16 E6 42-50) were at the high end of the range encountered (35 and 55 jig/ml, respectively).
Thus the results in these different assays led to a similar hierarchy of binding affinity.
Binding Affinity for HLA-A*0301 of Selected CEA Peptides
The selected 34 CEA specific peptides complying with the HLA-A*0301 peptide-binding motif described were tested in peptide-reconstitution assay in serial dilution on the HLA-A*0301 homozygous EKR cell line (Table 3) . Eight peptides did not show any significant binding affinity, illustrated by an '/2max 3=400 u,g/m! (Table 3) 
Human p53-, CEA-, and HIV-derived HLA-A*0201 binding peptides tested in the T2 assay and the peptide-reconstitution assay. Stated are the position of the peptide and f/zmax values for both assays. HPV 16-derived peptides were tested in the peptide-reconstitution assay and the molecular-binding assay. Stated are the 50% inhibition by competition (IC 50 ) values in the molecular-binding assay ) and the Vimax values in the peptide-reconstitution assay for binding to HLA-A*0301.
HLA, human leukocyte antigen; CEA, carcinoembryonic antigen; HIV. human immunodeficiency virus; HPV, human papUloma virus.
have such binding affinity that they can be designated as being potential HLA-A*0301-restricted CTL epitopes.
DISCUSSION
In the search for MHC class I binding peptides as targets for CTL-mediated immunotherapy, the potential effectiveness of which has been demonstrated in both murine models (31) (32) (33) and made likely in humans (34, 35) , there is a need to identify potential CTL epitopes binding to a great variety of HLA alleles to cover a majority of the population.
B-LCL with any HLA expression can be obtained rather easily. Therefore, we adapted the peptide-reconstitution assay as originally described (9) for use with such B-LCL lines and established the practical application of this assay for the HLA-A*0301 allele. Of course, having established the optimal circumstances for elution of this molecule, the technique might also be used to prepare antigenpresenting cells for primary CTL response induction.
The peptide reconstitution assay combines a number of advantages of the T2-btnding assay with the advantages of molecular binding assays. The assay does not involve radioactive components, and apart from a flow cytometer, no specialized equipment in the laboratory is required. Because B-LCL can be-applied, it is possible to study peptide-binding affinities for any HLA allele, provided an allele-specific antibody is available.
•. Whether peptide binding to isolated MHC class' 1 molecules differs from binding to the MHC class I in its native biological context, the intact, cell (-surface), has not been established yet. If such differences do occur, it seems likely that a cellular btnd- 334  11  TLFNVTRNDAR  523  12  RVDGNRQI1GY  38  15  TISPSYTYY  385  19  T1TVYAEPPK  281  20  • TVYAEPPK  283  20  ELFISNITEK  427  22  LFISNITEK  428  23  TISPLNTSY  207  25  HLFGYSWY  27  25  TITVSAELPK  459  29  KITPNNNGTY  610  38  NLPQHLFGY  23  40  FVSNLATGR  622  40  TVSAELPK  461  42  FISNITEK  429  -». -IIQNDTGFY  78  65  NVTRNDAR  526  70  SVTRNDVGPY  348  75  PVILNVLY  372  80  1ISPPDSSSY  563  85  GIQNSVSANRS  538  100  TISPSYTY  385  110  NVTRNDTASY  170  200  NVTRNDARAY  526  >400  N1TEKNSGLY  432  >400  TVTTITVY  278  >400  SISSNNSK  470  >400  SISSNNSK  114  >400  PVTLDVLY  550  >400  P1ISPPDSSY  562  >400  SVILNVLY  194  >400 '/iMax values of carcinoembryonic antigen (CEA)-derived peptides for binding to HLA-A*0301 in the peptidereconstitution assay in micrograms per milliliter. Stated are the amino acid sequence in one letter code, and the position of the first amino acid from the N-terminus of the protein.
HLA, human leukocyte antigen; CEA, carcinoembryonic antigen.
ing assay gives more realistic information about potential immunogenicity of the peptide when presented by the MHC class 1 molecule to the CTL.
To take advantage of the possibilities of the peptide-reconstitution assay, we adapted the assay for use on another HLA allele than the HLA-A*0201 described originally. Applying this strategy, in principle, all types of HLA alleles can be tested for peptide binding. Considerable differences in acid treatment conditions required for elution of HLA-A*0201 and HLA-A*0301 were encountered. These differences were allele specific and not cell-line dependent. The required acid treatment conditions for either of the alleles tested were identical in any of the cell lines tested, whether homozygous B-LCL, heterozygous B-LCL, or C1R variant.
Further investigation is needed to establish whether the differences in acid treatment conditions required for optimal elution of peptide from the respective MHC class I molecules is reflected in differenees in immunogenicity of peptides presented by these alleles. Such a relation is not unlikely, because so far, peptide-binding affinity is closely related to immunogenicity (2) .
When identical peptides were tested on different cell lines in the peptide reconstitution assay, FI curves for each peptide were identical in shape (Figs. 4 and 5 ), resulting in a comparable discrimination between strong, weak, and nonbinding peptides, irrespective of the use of homozygous, heterozygous, or the C1R A3 cell line.
When the homozygous and C1R A3 cell lines were used, the range of Vimax values was wider and, therefore, supposedly more accurate differentiation between binding affinities of the peptides tested is possible. '/sMax values were ~2 to 3 times lower, indicating a higher sensitivity for binding at low peptide concentrations when homozygous cells are used.
To validate the assay, p53-derived HLA-A*0201-binding peptides were tested in the peptide-reconstitution assay. Compared with the results from the T2 assa"y, the outcome of testing HLA-A*0201-binding p53 peptides in the peptide-reconstitution assay was mainly similar. Comparison of the HPVdenived peptides with different binding affinity known from the molecular binding assay (1) shows good correlation with the 'Amax values established using the peptide-reconstitution assay. One peptide (p53 264-272) appeared to have relatively lower binding affinity in the T2 assay than in the peptidereconstitution assay. A similar phenomenon was noted for HLA-A*0301 when the 1C 50 values of the HPV-derived peptides in the molecular-binding assay were compared with the findings in the peptidereconstitution assay. Similar discrepancies in ranking of binding affinity were found before when p53 peptide binding was studied in the T2 binding and T2 competition assay (13) .
Such discrepancies might be caused by the considerable differences in incubation time between the peptide-reconstitution assay and the other test: whereas association rate and dissociation rate together cause an equilibrium (molecular binding) or stable effect (T2) reached during overnight incubation, a high association rate could cause features of high binding affinity in the peptide-reconstitution assay. The presence of the native biological context might also contribute to such discrepancies.
The peptide-reconstitution assay is a valid and useful instrument in determining peptide-binding affinity to MHC class I; by the application of B-LCL, any phenotype can be studied, provided an allelespecific antibody is available. We demonstrated here that the used cells are preferably homozygous for the HLA allele studied, because this results in higher sensitivity, especially at low peptide concentrations; however, in the unlikely event that a homozygous B-LCL cannot be made avaüable, a heterozygous cell line may be used. Therefore, it may be a very useful tool in the development of CTLmediated immunotherapy.
We applied the peptide-reconstitution assay using a B-LCL line homozygous for HLA-A*0301 to test binding affinity of 34 binding-motif-selected CEAspecific peptides. Six of these had binding affinities in the same range as high-affinity binding peptides of viral origin and can therefore be designated to be potential CTL epitopes.
